Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-free ZR2 regimen in elderly unfit patients with newly diagnosed diffuse large B-cell lymphoma
ChiCTR2400079581Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, lenalidomide and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Qilu Hospital of Shandong University. Primary endpoints: 18-month progression-free survival and overall survival. Started Jan 2024; status: recruiting.
02
Drugs
zanubrutiniblenalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400079581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079581.